# Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

> **NCT01397695** · PHASE2 · COMPLETED · sponsor: **University of California, San Diego** · enrollment: 20 (actual)

## Conditions studied

- Hereditary Hemorrhagic Telangiectasia (HHT)

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01397695
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2019-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01397695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01397695, "Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01397695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*